Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer

Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial

(2011) Josefina Alberú et al.   TRANSPLANTATION

Switch to a Sirolimus-Based Immunosuppression in Long-Term Renal Transplant Recipients: Reduced Rate of (Pre-)Malignancies and Nonmelanoma Skin Cancer in a Prospective, Randomized, Assessor-Blinded, Controlled Clinical Trial

(2010) R. Salgo et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The mTOR Pathway: A New Target in Cancer Therapy

(2010) L. Ciuffreda et al.   CURRENT CANCER DRUG TARGETS

Distinct Immunohistochemical Phenotype of Nonmelanoma Skin Cancers Between Renal Transplant and Immunocompetent Populations

(2010) Alex Gutiérrez-Dalmau et al.   TRANSPLANTATION

Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

(2009) Francesco P. Schena et al.   TRANSPLANTATION

Skin Cancer in Organ Transplant Recipients-Where Do We Stand Today?

(2008) C. Ulrich et al.   AMERICAN JOURNAL OF TRANSPLANTATION